1009 completed, 295 terminated, 266 recruiting, 155 unknown. 2031 Phase 2, 408 Phase 1, 86 Phase 3.
Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) - Metastatic Castration-Resistant Prostate Cancer, mCRPC | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 192 | 2027-06-28 | 2026-09-30 |
| Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer Antiandrogen Therapy, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 24 | 2027-02-26 | 2026-11-12 |
| HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer Clomiphene Citrate 25mg - Prostate Cancer | Phase 2 | Not yet recruiting | University of Nebraska | 83 | 2027-01-31 | 2026-10-20 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The ALTAR-100 Trial ALT-100 - Prostate Cancer Metastatic to Bone | Phase 1 / Phase 2 | Not yet recruiting | University of Florida | 42 | 2027-01-01 | 2026-11-04 |
| RELEASE Ph2 RT-310 BPH Study RT-310 PK, Placebo, RT-310 - Benign Prostatic Hyperplasia (BPH) | Phase 2 | Not yet recruiting | Resurge Therapeutics Inc. | 86 | 2027-01-01 | 2026-11-10 |
| Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients Tamoxifen - Hypogonadism, Prostate Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 96 | 2026-12-31 | 2026-10-22 |
| PSMA-specific CAR-T Cell Therapy 4SCAR-PSMA T cells - PSMA Positive Tumors or Tumor Tissues | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2026-12-31 | 2026-10-30 |
| Whole Versus Partial Gland Boost During Prostate SBRT Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Not yet recruiting | University of Nebraska | 160 | 2026-12-25 | 2026-11-03 |
| Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC) Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitors (ARPIs) - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 2 | Not yet recruiting | University of Nebraska | 56 | 2026-12-24 | 2026-11-03 |
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer Prostate Only Radiation Therapy (PORT), Prostate + Whole Pelvis Radiation Therapy (P-WPRT) - Prostate Cancer | Phase 2 | Not yet recruiting | AHS Cancer Control Alberta | 250 | 2026-12-01 | 2026-11-04 |
| Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan - Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2026-12-01 | 2026-11-02 |
| PSMA PET/MRI for Predicting and Detecting Prostate Cancer PSMA PET, MRI, 18F-DCFPyL - Prostate Cancer, High-Risk Localized Prostate Cancer | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 120 | 2026-12-01 | 2026-11-09 |
| STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma STAR0602, Nivolumab - NSCLC, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 67 | 2026-11-18 | 2026-11-13 |
| Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance TriAdeno vaccine, N-803 - Adenocarcinoma, Prostate Cancer | Phase 2 | Recruiting | National Cancer Institute (NCI) | 52 | 2026-11-18 | 2026-11-13 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-18 | 2026-11-13 |
| Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 64 | 2026-11-15 | 2026-10-19 |
| Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer Ifinatamab Deruxtecan, Positron Emission Tomography (PET)/Computerized Tomography (CT), Computerized Tomography (CT)/ Magnetic Resonance Imaging (MRI) - Neuroendocrine Prostate Cancer (NEPC), Metastatic Prostate Adenocarcinoma | Phase 2 | Not yet recruiting | Rahul Aggarwal | 30 | 2026-11-07 | 2026-11-09 |
Showing 20 of 2031. Sign in to see all of them.
Prostatic Neoplasms (1928) · Neoplasm Metastasis (100) · Neoplasms (96) · Breast Neoplasms (87) · Prostatic Hyperplasia (77) · Ovarian Neoplasms (55) · Carcinoma, Non-Small-Cell Lung (50) · Pancreatic Neoplasms (46) · Lung Neoplasms (43) · Colorectal Neoplasms (42) · Urinary Bladder Neoplasms (36) · Stomach Neoplasms (32) · Uterine Cervical Neoplasms (31) · Endometrial Neoplasms (30) · Melanoma (30)
Genital Diseases (2028) · Urogenital Diseases (2028) · Male Urogenital Diseases (2023) · Genital Diseases, Male (2021) · Neoplasms by Site (1937) · Genital Neoplasms, Male (1930) · Urogenital Neoplasms (1928) · Neoplasms (1852) · Pathological Conditions, Signs and Symptoms (192) · Pathologic Processes (142) · Female Urogenital Diseases (122) · Female Urogenital Diseases and Pregnancy Complications (122) · Neoplasms by Histologic Type (116) · Neoplastic Processes (108)
Docetaxel (186) · Prednisone (160) · enzalutamide (116) · Abiraterone Acetate (112) · Leuprolide (100) · Radiotherapy (70) · Androgen Antagonists (66) · Magnetic Resonance Spectroscopy (65) · bicalutamide (64) · Goserelin (63) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (58) · apalutamide (50) · abiraterone (47) · gallium 68 PSMA-11 (41) · Specimen Handling (40)
National Cancer Institute (NCI) (112) · M.D. Anderson Cancer Center (55) · Memorial Sloan Kettering Cancer Center (51) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (33) · University Health Network, Toronto (31) · University of Washington (24) · AstraZeneca (21) · Dana-Farber Cancer Institute (21) · OHSU Knight Cancer Institute (21) · University of Wisconsin, Madison (21) · Mayo Clinic (20) · Jonsson Comprehensive Cancer Center (19) · University of California, San Francisco (18) · University of Michigan Rogel Cancer Center (18) · Alliance for Clinical Trials in Oncology (17)
United States (1336) · Canada (204) · United Kingdom (124) · France (103) · China (100) · Spain (78) · Germany (72) · Australia (70) · Italy (69) · Belgium (58) · Netherlands (52) · South Korea (41) · Poland (32) · Denmark (30) · Japan (30)
Robert J Amato, DO (11) · Mary-Ellen Taplin, MD (10) · Rahul Aggarwal, MD (8) · Ravi A Madan, M.D. (8) · Michael Morris, MD (7)
PMID 32994091, PMID 33270906, PMID 22894553, PMID 22932804, PMID 24722180, PMID 25687533, PMID 25712310, PMID 33465252, PMID 38421252, PMID 18777528, PMID 19455472, PMID 20818327, PMID 21106711, PMID 21791356, PMID 21802835, PMID 22747660, PMID 23533230, PMID 24321502, PMID 24412228, PMID 24510426, PMID 24772219, PMID 24974051, PMID 25475068, PMID 25614256, PMID 25786708, PMID 25936597, PMID 25937426, PMID 25963190, PMID 26659347, PMID 29240541, PMID 30189902, PMID 32897402, PMID 34350976, PMID 34529005, PMID 35027313, PMID 36001857, PMID 36710203, PMID 37058234, PMID 37482512, PMID 37496366, PMID 38421243, PMID 39074346, PMID 40016438, PMID 40645505, PMID 41044356, PMID 42186347, PMID 10661346, PMID 11106233, PMID 11586207, PMID 11828001
2017 (16), 2016 (14), 2023 (11), P30CA022453 (10), P30CA072720 (10), 2025 (9), U10CA031946 (9), P30CA015704 (8), P30CA016672 (8), 2019 (7), P30CA033572 (7), P50CA097186 (7), U01CA062491 (7), U10CA180820 (7), 2008 (6)